Only indicated for treatment of acute migraine. Risk of coronary vasospasm, myocardial ischemia and/or infarction, life-threatening cardiac rhythm disturbances, and death associated with use of 5-HT~1~ receptor agonists. Use of eletriptan not recommended in known or suspected ischemic or vasospastic heart disease or in likelihood of unrecognized coronary artery disease. Cerebral or subarachnoid hemorrhage, stroke, and other adverse cerebrovascular effects, some of which resulted in death, have occurred in patients treated with 5-HT~1~ receptor agonists. Patients with history of migraine may be at increased risk for certain cerebrovascular events (e.g. stroke, hemorrhage, transient ischemic attack). Peripheral vascular ischemia and colonic ischemia with abdominal pain and bloody diarrhea reported in patients treated with 5-HT~1~ receptor agonists. Substantial increases in blood pressure, including hypertensive crises, reported rarely following administration of 5-HT~1~ receptor agonists in patients with or without history of hypertension. Potentially life-threatening serotonin syndrome reported during concurrent therapy with 5-HT~1~ receptor agonists and SSRIs or SNRIs. Concurrent use of serotonin precursors (e.g. tryptophan) not recommended. Possible accumulation of eletriptan and/or its metabolites in melanin-rich tissues (such as the eye) over time, resulting in potential toxicity in these tissues with extended use. Not recommended for use in patients under 18 years of age. Increases in blood pressure may be more pronounced in geriatric patients. Use with caution in hepatic impairment. Use in severe hepatic impairment contraindicated.